AHR and breast cancer: Expression of WNT5A/B and β-catenin were correlated with markers of the cancer stem cell (CSC) phenotype, and AHR-antagonist treatment of MDA-MB-231 or SUM149 breast cancer cells resulted in significantly lower levels of WNT5A RNA.